CE Information and Faculty Disclosures

• TARGET AUDIENCE
  This program is intended for medical oncologists, hematology-oncology fellows and other healthcare providers involved in the treatment of lung cancer.
  
  LEARNING OBJECTIVES

  • Understand the cellular targets, structural components and mechanisms of action of available and investigational antibody-drug conjugates (ADCs) with documented activity in patients with lung cancer.
  • Evaluate available efficacy and safety findings with HER2-directed ADCs for patients with metastatic non-small cell lung cancer (NSCLC), and assess the optimal placement of this form of therapy in the current treatment algorithm.
  • Consider the biological rationale for the development of ADCs targeting TROP2 for NSCLC, and recognize available efficacy and safety findings with these agents in patients with relapsed/refractory disease.
  • Appreciate the incidence of HER3 overexpression in patients with NSCLC, and develop an understanding of the rationale for and available data with HER3-directed ADCs for metastatic NSCLC with an EGFR mutation.
  • Acknowledge the potential utility of c-Met as a therapeutic target in NSCLC, and recollect available and emerging efficacy and safety findings with novel c-Met-directed ADCs for patients with previously treated disease.
  • Recognize the spectrum, frequency, severity and optimal management of toxicities associated with novel ADCs with activity in lung cancer, and apply this information to facilitate the safe and effective use of these agents.
  • Recall the design of ongoing clinical trials evaluating novel ADCs or combination strategies with these agents for lung cancer, and counsel appropriate patients about availability and participation.

  ACCREDITATION STATEMENT
  Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
  
  CREDIT DESIGNATION STATEMENT
  Video Program: Research To Practice designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
  
  AMERICAN BOARD OF INTERNAL MEDICINE (ABIM) — MAINTENANCE OF CERTIFICATION (MOC)
  Successful completion of this CME activity, which includes participation in the evaluation component and a short post-test, enables the participant to earn up to 1.25 Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for each activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
  
  Please note, these programs have been specifically designed for the following ABIM specialty: medical oncology.
  
  AMERICAN BOARD OF SURGERY (ABS) — CONTINUOUS CERTIFICATION (CC)
  Successful completion of these CME activities, which includes participation in the evaluation component, enables the learner to earn credit toward the CME and Self-Assessment requirement(s) of the American Board of Surgery’s Continuous Certification program. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABS credit.
  
  Please note, these programs have been specifically designed for the following ABS practice area: complex general surgical oncology.
  
  PRIVACY POLICY
  Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information.
  
  HOW TO USE THIS CME ACTIVITY
  Video Program: This CME activity consists of a video component. To receive credit, the participant should review the CME information, watch the video, complete the post-test with a score of 80% or better and fill out the evaluation located at ResearchToPractice.com/ASCO2024/ADCLung/Video/CME.
  
  CONTENT VALIDATION AND DISCLOSURES
  Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.
  
  FACULTY — The following faculty reported relevant financial relationships with ineligible entities:
  
  Rebecca S Heist, MD, MPH
  Associate Professor of Medicine
  Harvard Medical School
  Thoracic Oncology
  Massachusetts General Hospital Cancer Center
  Boston, Massachusetts
  
  Consulting Agreements: AbbVie Inc, AstraZeneca Pharmaceuticals LP, Biohaven, Claim Therapeutics, Daiichi Sankyo Inc, Lilly, Merck, Novartis, Regeneron Pharmaceuticals Inc, Sanofi; Contracted Research: Agios Pharmaceuticals Inc, Corvus Pharmaceuticals, Daiichi Sankyo Inc, Erasca, Lilly, Mirati Therapeutics Inc, Mythic Therapeutics, Novartis, Turning Point Therapeutics Inc.
  
  Luis Paz-Ares, MD, PhD
  Chair of the Medical Oncology Department at the Hospital Universitario 12 de Octubre
  Associate Professor at the Universidad Complutense
  Head of the Lung Cancer Unit at the National Oncology Research Center
  Madrid, Spain
  
  Advisory Committees: Amgen Inc, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Bristol Myers Squibb, Daiichi Sankyo Inc, GSK, Janssen Biotech Inc, Lilly, Merck, Mirati Therapeutics Inc, MSD, Novartis, Pfizer Inc, PharmaMar, Roche Laboratories Inc, Sanofi, Servier Pharmaceuticals LLC, Takeda Pharmaceuticals USA Inc; Boards of Directors: Altum Sequencing, STAb Therapeutics; Speakers Bureaus: AstraZeneca Pharmaceuticals LP, Bristol Myers Squibb, GSK, Janssen Biotech Inc, Lilly, Mirati Therapeutics Inc, MSD, PharmaMar, Sanofi.
  
  MODERATOR
  Jacob Sands, MD
  Physician
  Dana-Farber Cancer Institute
  Assistant Professor
  Harvard Medical School
  Boston, Massachusetts
  
  Advisory Committee: Curadev; Consulting Agreements: Amgen Inc, AstraZeneca Pharmaceuticals LP, Boehringer Ingelheim Pharmaceuticals Inc, Daiichi Sankyo Inc, Gilead Sciences Inc, Lilly, Medtronic Inc, Pfizer Inc, PharmaMar, Sanofi; Contracted Research: Amgen Inc, Harpoon Therapeutics; Data and Safety Monitoring Board/Committee: Johnson & Johnson Pharmaceuticals.
  
  RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.
  
  This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.
  
  This activity is supported by educational grants from AbbVie Inc, AstraZeneca Pharmaceuticals LP, and Daiichi Sankyo Inc.
  
  Release date: July 2024
  Expiration date: July 2025
  
  After completing the post-test, learners may download and review the answers here in order to identify further areas of study.